SALL2 expression was significantly lower in the tamoxifen‐treated ER+ breast tumors with relapse or metastasis than that in the primary tumors without relapse or metastasis (Fig 2F; Appendix Table S4). This evidence concerns the gene ESR1 and breast neoplasm.